The courtroom had a particular smell on the first day of a major trial.
Not anything specific — just the accumulated weight of the building's history, the institutional deodorant of a federal courthouse, and the specific tension of forty-seven people sitting in gallery seats behind the plaintiff's table waiting to find out if the law was going to do something about the thing that had happened to them.
Margaret Holt was in the third row. Fifty-nine now. She'd had the cardiac event at fifty-eight, survived it with the specific luck of a woman whose husband was a former EMT, and had been living for the past two years with an arrhythmia that her cardiologist described as "manageable but permanent." She hadn't missed a single day of the trial's jury selection. She wasn't going to miss a day of the trial.
I saw her when I came through the doors at 8:47 AM.
I didn't wave. She wasn't my witness yet — she'd testify in week two — and the relationship between a trial attorney and a plaintiff witness required specific management before direct examination. But I acknowledged her with a nod, and she returned it with the particular expression of someone who had been waiting a long time for a specific moment.
Marcus Williams was already at the plaintiff's table setting up the evidence presentation system when I arrived. He'd been at the office since six — I knew because he'd sent me a case note at 6:23 AM about a minor exhibit indexing issue he'd resolved independently. That was Marcus now: problems he could solve appeared and disappeared without reaching my desk.
Dr. Rowe was beside him, straight-backed, her hands organized in front of her with the controlled composure of someone who had been preparing for this moment for eighteen months and had decided this morning that the preparation was complete.
"Ready?" I said.
"No," she said. "But I'm here."
"That's the whole job," I said. "The ready part happens in the room."
Sean Cahill was at the adjacent table with his two SEC co-counsel, reviewing documents with the focused efficiency I'd come to recognize as his operating mode — quiet, systematic, completely devoid of the performance that some prosecutors brought into courtrooms. He looked up when I sat down and gave a brief nod. We'd coordinated our opening statement approaches the previous afternoon. The SEC's opening was two minutes, entirely focused on the securities fraud dimension — every investor disclosure that had been built on falsified clinical data. It didn't overlap with mine and didn't step on it.
Eleanor Marsh arrived at 8:52.
I'd researched Marsh extensively — the System had catalogued twelve of her pharmaceutical defense victories over thirty years, identified her characteristic opening gambit of creating interpretive ambiguity early rather than directly contesting evidence, and flagged her particular skill at making juries feel that certainty was arrogance. She was sixty-one, silver-haired, with the unhurried precision of someone who had stopped performing command decades ago because the real thing was cheaper.
[ Argument Crusher: Eleanor Marsh — profile. Defense style: doubt cultivation via complexity. Strength: makes technical interpretation seem contested. Weakness: her strategy requires the jury to be confused. If jury comprehension is high, her planted doubts don't take root. ]
I was aware of this.
The whole case was built on making sure the jury comprehended what had been done.
Judge Patricia Chen took the bench at nine sharp, which was her custom, and the quality of her entrance told everyone in the room that the delays Covington had managed to create in the pre-trial period were finished. This courtroom was running on her schedule now.
"Counsel, opening statements. Plaintiff."
I stood.
I didn't approach the podium. I'd decided weeks ago to stand at the center of the well — the same position I'd used in the Hessington trial, the same choice to reduce physical distance between myself and the jury.
I looked at the twelve people in the box.
I did not start with the data.
"Margaret Holt was fifty-eight years old," I said. "She had controlled hypertension for twelve years — well-managed, medication-adjusted, stable. Her cardiologist reviewed the available treatment options in June 2014 and prescribed Corvalox because the clinical trial data filed with the FDA said it was safe for patients with her profile." I paused. "Margaret Holt had a cardiac event in October 2014. She survived — barely, because her husband had EMT training and knew what was happening before the ambulance arrived." I let that settle. "She is in this room. She is in the third row. She is one of forty-seven people in this room who have stories like that one."
The jury looked at the gallery. They found Margaret Holt. She was already looking at me.
"There are also eight people in this room," I said, "who had evidence — documented, timestamped, algorithmic evidence — that stories like Margaret's were possible. Who had that evidence before they filed the FDA application. Who modified the software that processed the clinical trial data so that the evidence would disappear before anyone in a position to stop this drug's approval could see it."
I looked at the Meridian side of the courtroom.
"Those eight people made a choice. This case is about whether that choice has consequences."
I sat down.
Four pages of prepared remarks. Delivered in under six minutes.
Zane, behind the gallery rail, didn't look at me. He looked at the jury. I looked at the jury too, in my peripheral vision.
[ Win Rate Calculator: Opening statement impact assessment. Jury behavioral analysis — 8 members engaged at maximum attention level, 4 members engaged at high level. Initial plaintiff-favorable lean: 8-4. ]
Better than Hessington's opening day.
Eleanor Marsh stood the way she did everything — without hurry, with the specific efficiency of someone who had been in this room before and knew exactly how much space she occupied and how to use it.
"Ladies and gentlemen," she said, "you've heard a compelling story from opposing counsel. And it is a story — constructed, selected, edited, and delivered with considerable skill. My job over the next several weeks is to show you the other story. The complete story."
She moved toward the jury box at the same angle I'd noticed her use in the three trial transcripts I'd reviewed.
"Meridian Pharmaceuticals employs six thousand people. It operates in twenty-two countries. Its research division is led by scientists who have spent their careers working to develop medications that help real people — people like Margaret Holt, who you heard about this morning." She paused. "Clinical trials are among the most scientifically complex undertakings in medicine. The process of evaluating adverse events — distinguishing between an event caused by a drug and an event caused by the patient's underlying condition — requires expertise, judgment, and interpretation of ambiguous data. Scientists can look at the same data and reach different conclusions. That is not fraud. That is science."
She let that land.
"Dr. Rowe, who you will hear from later this week, is a research scientist. She is intelligent, capable, and genuinely convinced of her interpretation of this data. She is also a scientist whose promotion was denied in the year before she began building this case, whose internal concerns were reviewed by multiple experienced colleagues who reached different conclusions, and whose interpretation of one particular software parameter change — made during routine maintenance — forms the foundation of plaintiff's entire theory."
She returned to her table.
"We will show you, with the testimony of scientists more qualified in this specific area of pharmaceutical statistics than Dr. Rowe, that her interpretation is an interpretation — not a fact, not a certainty, not the only reasonable reading of the evidence. We will show you that every decision Meridian made in the preparation and submission of this drug's clinical trial data was consistent with FDA guidelines, industry standards, and accepted scientific practice. And we will show you that the 47 people in this gallery — real people, genuinely suffering — deserve to understand the true cause of their conditions rather than a corporate defendant built from selective facts."
She sat down.
The jury looked thoughtful.
[ Argument Crusher: Marsh opening assessment. Strategy confirmed: complexity cultivation + motive attack. Strongest planted doubt: 'interpretation, not certainty.' Most dangerous to address: directly engaging on 'different conclusions' without appearing to condescend. Dr. Chen's testimony is the response — make interpretation irrelevant by showing the code change. ]
I wrote one note on my legal pad: Certainty comes from the zero.
After the first day session ended, Zane was waiting in the corridor with coffee he'd gotten from the street cart outside.
"Your opening was the best I've heard from you," he said. "And I've heard a lot."
"I had good material."
"You always have good material." He handed me the coffee. "Today you knew what to do with it."
I thought about what "knowing what to do" meant at this point in a career. It was five years of cases accumulated into instinct — the Hessington trial teaching me that names were more powerful than statistics, the Forstman case teaching me that clean evidence stated plainly was more devastating than evidence dramatized, Mike's defense teaching me that the gap between a credential and a competence could be made visible if you named it right.
Everything I'd built was in that opening statement. Six minutes of it.
"Marsh is good," I said.
"Better than Jessica?"
I thought about it. "Different. Jessica had more charisma in the room but she preferred argument to psychology. Marsh is planting uncertainty. She's not trying to win Day 1 — she's trying to make the jury uncertain enough that they're open to her version by the time the technical evidence arrives."
Zane nodded. "What's your answer to that?"
"The zero," I said. "She can call the 4.7% a contested interpretation. She can't explain why it became 0%. That's not an interpretation difference. That's a number that can't exist without the modification."
He looked at me over the coffee cup.
"Win the case, Scott," he said.
I texted Donna from the courthouse steps.
Day 1 done. Eight-four initial lean. Marsh is better than I expected.
Her response came in two minutes, which meant she'd been watching her phone. She was managing two active Paulsen Consulting engagements from a position that was now six weeks from delivering her first child, and she was still watching her phone for trial updates.
How much better?
The kind that makes this interesting.
Good. You don't do well with easy.
No. I don't.
I walked to the subway. The January air was doing what January did — committed and cold, the specific New York cold that didn't negotiate.
Forty-six days of trial ahead.
The jury had heard about Margaret Holt and they'd heard about scientific interpretation and they'd heard the word "zero" from Eleanor Marsh's own lips, in the context of Dr. Rowe's "alternative reading" of routine software maintenance.
Tomorrow I was beginning to build what the zero meant.
A LOT More chapters reign FREE upon unwrittenrealm.com.
• Normal | $8 — 15 chapters ahead
• Advanced | $11 — 20 chapters ahead
• Overlord | $19 — 25 chapters ahead, plus request a refinement (plot, character, system) on any of my novels
patreon.com/TheFinex5
▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰
― DECREE ―
More chapters reign FREE upon unwrittenrealm.com.
The throne acknowledges.
▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰▰